Although CDK4/6 inhibitors have revolutionized treatment for breast cancer, and promising antitumor effects of various inhibitors have also been witnessed in clinical or preclinical trials, resistance to CDK4/6 inhibitors is emerging. This evidence concerns the gene CDK4 and breast carcinoma.